Posted June 27, 2024
Gov. Ron DeSantis signed HB885 into law on June 18th, which expands patient access to biomarker testing, a key tool used by physicians to identify the most effective treatment of cancer and other diseases. In the case of a cancer diagnosis, biomarker testing allows doctors to develop a personalized treatment plan. It opens the door...
Posted June 24, 2024
The Centers for Medicare & Medicaid Services Innovation Center (CMMI) announced it is reopening the Enhancing Oncology Model for a second cohort of participants and payers. The second cohort will begin on July 1, 2025, and end on June 30, 2030, for a 5-year model performance period. For more details and eligibility criteria, please read...
Posted June 24, 2024
Bipartisan members of the Unites States House of Representatives and Senate have reintroduced the Association for Clinical Oncology (ASCO)-endorsed Improving Seniors’ Timely Access to Care Act (H.R.8702/S.4532) to streamline prior authorization within Medicare Advantage (MA) plans. The bill currently has 175 combined cosponsors (45 senators and 130 representatives). Last Congress, this legislation unanimously passed in...
Posted June 7, 2024
On May 28, Sagent Pharmaceuticals announced a voluntary nationwide recall of two lots of docetaxel injection (80 mg per 8 mL multidose vials and 160 mg per 16 mL multidose vials). The move was prompted by a customer complaint regarding possible particulate matter. Although no adverse events have been reported thus far, injection of particulate...
Posted March 26, 2024
The American Society for Colposcopy and Cervical Pathology (ASCCP) is proud to announce a major milestone by the groundbreaking Enduring Guidelines initiative, aimed at revolutionizing the fight against cervical cancer. In a bid to ensure the most current and effective clinical management strategies, the Enduring Guidelines process seeks to integrate emerging technologies and the latest...
Posted February 26, 2024
On February 11, a federal judge dismissed a drug industry trade group’s legal challenge to halt Medicare drug price negotiations, ruling that it lacked standing. The complaint was filed by the Pharmaceutical Research and Manufacturers of America (PhRMA), the Global Colon Cancer Association (GCCA), and the National Infusion Center Association (NICA) in June of last...
Posted February 21, 2024
February 14, 2024 marked day 30 of the 60-day Florida Legislative Session, and the FMA remains hard at work to help physicians practice medicine. This midpoint report by FMA Assistant General Counsel Mary Thomas, Esq., summarizes some of the most notable bills that could affect you and your patients, where each one stands in the...
Posted February 21, 2024
The 2024 Medicare Participation Physicians / Suppliers Directory (MEDPARD) is now available. As in the past, there will be no hardcopy distributions. Beneficiaries can use the Physician Compare website or contact 1-800-MEDICARE for assistance in locating a participating supplier near their home.
Posted February 1, 2024
The Centers for Medicare & Medicaid Services (CMS) has released guidance on the billing requirements for G2211 to ensure that coding and billing staff know when to bill the code, the necessary documentation requirements, and the associated patient coinsurance and deductibles. In the 2024 Medicare Physician Fee Schedule Final Rule, CMS finalized coding and reimbursement...
Posted January 25, 2024
On Thursday evening, Congress passed another short-term spending bill, funding the federal government into early March. Unfortunately, the bill only extended healthcare-related policies that were included in the previous funding bill and does not include any new healthcare policies, such as an increase in the Medicare Physician Fee Schedule. The previous spending bill funded a...
Posted January 17, 2024
Ascentage Pharma (6855.HK) announced that olverembatinib (R&D Code: HQP1351) has been included in the latest guidelines from the National Comprehensive Cancer Network (NCCN) for the management of Chronic Myeloid Leukemia (CML),[1] marking a major development in global recognition for its best-in-class drug candidate, which has been approved in China for the management of tyrosine kinase...
Posted January 17, 2024
On January 17, 2024, the Centers for Medicare and Medicaid Services released the “CMS Interoperability and Prior Authorization final rule (CMS-0057-F).” The rule would place new requirements on Medicare Advantage (MA) organizations, state Medicaid and Children’s Health Insurance Program (CHIP) Fee-for-Service programs, Medicaid managed care plans, CHIP managed care entities, and Qualified Health Plan (QHP)...
© 2021 FLASCO | Premium Website Design by The HDG
